Scientometrics
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 24, 2023; 14(10): 420-439
Published online Oct 24, 2023. doi: 10.5306/wjco.v14.i10.420
What should be the future direction of development in the field of prostate cancer with lung metastasis?
Zhi-Guang Huang, Yi Chen, Tong Wu, Bin-Tong Yin, Xiao Feng, Sheng-Hua Li, Dong-Ming Li, Gang Chen, Ji-Wen Cheng, Juan He
Zhi-Guang Huang, Yi Chen, Tong Wu, Bin-Tong Yin, Dong-Ming Li, Gang Chen, Juan He, Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Xiao Feng, Department of Radiology, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Sheng-Hua Li, Ji-Wen Cheng, Department of Urology, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Author contributions: Huang ZG, Chen Y, Feng X, Li SH, Li DM, Chen G, Cheng JW, and He J conceived and designed the research; Chen Y, Wu T, and Yin BT did the experiments, analyzed the data and made all the graphs; Huang ZG, Feng X, Li SH, Li DM, Chen G, Cheng JW, and He J revised the manuscript; and all authors have read and approve the final manuscript.
Supported by the Natural Science Foundation of Guangxi, China, No. 2020GXNSFBA238017; Guangxi Zhuang Autonomous Region Health Commission Self-financed Scientific Research Project, No. Z20200963.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Juan He, MM, Doctor, Department of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. hejuan@stu.gxmu.edu.cn
Received: August 14, 2023
Peer-review started: August 14, 2023
First decision: August 24, 2023
Revised: September 12, 2023
Accepted: September 25, 2023
Article in press: September 25, 2023
Published online: October 24, 2023
Abstract
BACKGROUND

Since the start of the 21st century, prostate cancer with lung metastasis (PCLM) has accumulated significant scientific research output. However, a systematic knowledge framework for PCLM is still lacking.

AIM

To reconstruct the global knowledge system in the field of PCLM, sort out hot research directions, and provide reference for the clinical and mechanism research of PCLM.

METHODS

We retrieved 280 high-quality papers from the Web of Science Core Collection and conducted a bibliometric analysis of keywords, publication volume, and citation frequency. Additionally, we selected differentially expressed genes from global high-throughput datasets and performed enrichment analysis and protein-protein interaction analysis to further summarize and explore the mechanisms of PCLM.

RESULTS

PCLM has received extensive attention over the past 22 years, but there is an uneven spatial distribution in PCLM research. In the clinical aspect, the treatment of PCLM is mainly based on chemotherapy and immunotherapy, while diagnosis relies on methods such as prostate-specific membrane antigen positron emission tomography/computed tomography. In the basic research aspect, the focus is on cell adhesion molecules and signal transducer and activator of transcription 3, among others. Traditional treatments, such as chemotherapy, remain the mainstay of PCLM treatment, while novel approaches such as immunotherapy have limited effectiveness in PCLM. This study reveals for the first time that pathways related to coronavirus disease 2019, cytokine-cytokine receptor interaction, and ribosome are closely associated with PCLM.

CONCLUSION

Future research should focus on exploring and enhancing mechanisms such as cytokine-cytokine receptor interaction and ribosome and improve existing mechanisms like cadherin binding and cell adhesion molecules.

Keywords: Prostate cancer, Lung metastasis, Chemotherapy, Immunotherapy, Bibliometric analysis, Enrichment analysis

Core Tip: Discovering new insights into prostate cancer with lung metastasis (PCLM), this study presents a systematic analysis of 280 high-quality papers and global datasets. The uneven distribution of PCLM research is highlighted. Notably, this study uncovers the association of PCLM with pathways related to coronavirus disease 2019, cytokine-cytokine receptor interaction, and ribosomes. While traditional treatments remain crucial, novel approaches like immunotherapy show limited effectiveness. Future research should prioritize exploring mechanisms such as cytokine-cytokine receptor interaction and ribosomes while enhancing existing mechanisms like cell adhesion molecules. This study’s innovative findings contribute to the advancement of PCLM research, stimulating further exploration and potential improvements in diagnosis and treatment strategies.